Findings published today in Nature Cancer from Charles Mullighan, MBBS (Hons), MSc, MD, deputy director of the St. Jude Comprehensive Cancer Center, Department of Pathology, and collaborators show ...
Sonrotoclax is a next-generation and potentially best-in-class investigational B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Studies in the lab and ...
In this interview, industry experts Mathieu Bennet and Dustin Whitson explore how automation and single-cell technologies are transforming high-throughput B-cell cloning for antibody discovery. Can ...
New study demonstrates how high-affinity B cells 'bank' their best traits instead of rolling the dice and risking deleterious mutations, with implications for better vaccine design. A vaccine's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback